Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | PKM | P14618 | 6/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.49 |
| ▸ | HTR6 | P50406 | 4/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | PKLR | P30613 | 2/20 | 0.45 |
| ▸ | CPT2 | P23786 | 1/20 | 0.44 |
| ▸ | CPT1A | P50416 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5468990 | 0.92 | PKM (0.57) | NPC1PKMMEN1KMT2AALDH1A1 | |
| SCHEMBL25754845 | 0.85 | PKM (0.52) | NPC1PKMMEN1KMT2AALDH1A1 | |
| SCHEMBL23847013 | 0.85 | NR1H3 (0.53) | NPC1PKMMEN1KMT2AALDH1A1 | |
| SCHEMBL23847011 | 0.85 | PKM (0.52) | NPC1PKMMEN1KMT2AALDH1A1 | |
| SCHEMBL5828166 | 0.85 | PKM (0.51) | NPC1PKMMEN1KMT2AALDH1A1 | |
| SCHEMBL31750670 | 0.84 | NPC1 (0.62) | NPC1PKMMEN1KMT2AALDH1A1 | |
| SCHEMBL34474489 | 0.82 | NPC1 (0.53) | NPC1PKMMEN1KMT2AALDH1A1 | |
| SCHEMBL5474787 | 0.81 | NPC1 (0.58) | NPC1PKMMEN1KMT2AALDH1A1 | |
| SCHEMBL31751269 | 0.81 | NPC1 (0.55) | NPC1PKMMEN1KMT2AALDH1A1 | |
| SCHEMBL30110984 | 0.81 | PKM (0.62) | NPC1PKMMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174523-A1 | BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | AMATHUS THERAPEUTICS, INC. (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230174523-A1 | BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | AMATHUS THERAPEUTICS, INC. (US) | 2023-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174523-A1 | BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | TRAP1, PINK1, TP53BP1 | NPC1 1821/4885PKM 2001/4885MEN1 3902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.